GENET-news
To stay informed you can subscribe to the GENET-news list.
2007-06-29 | permalink
SemBioSys presents positive insulin data from GE pharma crops
SemBioSys Genetics Inc., a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular disease, today announced positive preclinical data supporting the development of plant-derived recombinant human insulin. The Company presented its findings at the 67th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. Specifically, the Company’s abstract and poster presentation highlighted its recent accomplishments in the development of a highly-scalable, lowcost source of insulin.
Overview
News
2007-06-29 | permalink
SemBioSys presents positive insulin data from GE pharma crops
SemBioSys Genetics Inc., a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular disease, today announced positive preclinical data supporting the development of plant-derived recombinant human insulin. The Company presented its findings at the 67th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. Specifically, the Company’s abstract and poster presentation highlighted its recent accomplishments in the development of a highly-scalable, lowcost source of insulin.
GENET-news & GENET-forum
GENET-news is providing a daily news service on a range of topics regarding genetic engineering. We are screening the worldwide English news, press releases and other publications to provide you with a strategic selection of information. GENET-news enables you to stay informed about all aspects of the global controversy around GE technologies and GE organisms. You can subscribe by 
email.
The GENET-forum list provides you with additional background information and more voluminous reports. It is only open for GENET members. Please contact the coordinator for membership and subscription.